Oral medicine to slow damage from pulmonary arterial hypertension
Development of a novel disease modifying oral therapy for pulmonary arterial hypertension.
A new oral drug called VN-1032 aims to slow blood-vessel damage in people with pulmonary arterial hypertension.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vasculonics, LLC NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11193989 on NIH RePORTER |
What this research studies
This project is developing VN-1032, an oral medicine designed to change the course of pulmonary arterial hypertension by targeting the AhR pathway and lowering ADMA, two drivers of blood-vessel injury. The team has optimized the chemical and seen promising results in laboratory and animal models that mimic human PAH. Ongoing work focuses on final preclinical testing to support future human studies and regulatory steps. If you have PAH, this work is intended to move beyond symptom relief toward treatments that address the underlying vascular disease.
Who could benefit from this research
Good fit: Ideal candidates would be adults diagnosed with pulmonary arterial hypertension, especially those with progressive disease despite current vasodilator treatments.
Not a fit: People with pulmonary hypertension caused by left-heart disease or lung disease, or anyone without PAH, are unlikely to benefit from this therapy.
Why it matters
Potential benefit: If successful, VN-1032 could slow or stop PAH progression and potentially improve survival beyond current symptom-focused therapies.
How similar studies have performed: Targeting the AhR and ADMA pathways for PAH is relatively new: preclinical studies show promise but no approved therapies yet use this approach.
Where this research is happening
Indianapolis, United States
- Vasculonics, LLC — Indianapolis, United States (Active)
Researchers
- Principal investigator: Singh, Jaipal — Vasculonics, LLC
- Study coordinator: Singh, Jaipal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.